Integrated Investment Consultants LLC Lowers Stake in Pfizer Inc. (NYSE:PFE)

Key Points

• Integrated Investment Consultants LLC reduced its holdings in Pfizer by 75.9% during the first quarter, leaving them with 32,065 shares valued at $813,000.
• Several institutional investors increased their positions in Pfizer, with notable growth from Geode Capital Management LLC (up 2.5%) and Massachusetts Financial Services Co. (up 7.5%) during the fourth quarter.
• Analysts have mixed sentiments about Pfizer, with a consensus average rating of "Hold" and a target price of $28.55, while recent price targets have fluctuated between $24.00 and $32.00.

Integrated Investment Consultants LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 75.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,065 shares of the biopharmaceutical company's stock after selling 101,240 shares during the period. Integrated Investment Consultants LLC's holdings in Pfizer were worth $813,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC lifted its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. bought a new position in Pfizer in the 1st quarter valued at approximately $28,000. Bernard Wealth Management Corp. bought a new position in Pfizer in the 4th quarter valued at approximately $30,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer in the 1st quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

PFE traded down $0.07 on Tuesday, hitting $24.25. The company's stock had a trading volume of 18,198,608 shares, compared to its average volume of 45,150,988. The company's 50 day simple moving average is $24.32 and its 200-day simple moving average is $24.63. The firm has a market cap of $137.84 billion, a P/E ratio of 17.56, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the company posted $0.82 EPS. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.09%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Jefferies Financial Group upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Bank of America upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Finally, The Goldman Sachs Group upped their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.